PL3317300T3 - Dwuswoiste przeciwciała do zastosowania do immunoterapii nowotworu - Google Patents

Dwuswoiste przeciwciała do zastosowania do immunoterapii nowotworu

Info

Publication number
PL3317300T3
PL3317300T3 PL16744669T PL16744669T PL3317300T3 PL 3317300 T3 PL3317300 T3 PL 3317300T3 PL 16744669 T PL16744669 T PL 16744669T PL 16744669 T PL16744669 T PL 16744669T PL 3317300 T3 PL3317300 T3 PL 3317300T3
Authority
PL
Poland
Prior art keywords
cancer immunotherapy
double antibodies
antibodies
double
immunotherapy
Prior art date
Application number
PL16744669T
Other languages
English (en)
Inventor
Mariangela Figini
Alessandro SATTA
Alessandro Massimo Gianni
Massimo DI NICOLA
Original Assignee
Fondazione Irccs Istituto Nazionale Dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondazione Irccs Istituto Nazionale Dei Tumori filed Critical Fondazione Irccs Istituto Nazionale Dei Tumori
Publication of PL3317300T3 publication Critical patent/PL3317300T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL16744669T 2015-07-01 2016-07-01 Dwuswoiste przeciwciała do zastosowania do immunoterapii nowotworu PL3317300T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15174741.7A EP3112381A1 (en) 2015-07-01 2015-07-01 Bispecific antibodies for use in cancer immunotherapy
EP16744669.9A EP3317300B1 (en) 2015-07-01 2016-07-01 Bispecific antibodies for use in cancer immunotherapy
PCT/EP2016/065577 WO2017001681A1 (en) 2015-07-01 2016-07-01 Bispecific antibodies for use in cancer immunotherapy

Publications (1)

Publication Number Publication Date
PL3317300T3 true PL3317300T3 (pl) 2021-05-31

Family

ID=53498900

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16744669T PL3317300T3 (pl) 2015-07-01 2016-07-01 Dwuswoiste przeciwciała do zastosowania do immunoterapii nowotworu

Country Status (18)

Country Link
US (1) US10813995B2 (pl)
EP (2) EP3112381A1 (pl)
JP (1) JP6876006B2 (pl)
KR (1) KR102933838B1 (pl)
CN (1) CN108602886B (pl)
AU (1) AU2016285118B2 (pl)
CA (1) CA2990517C (pl)
CY (1) CY1123839T1 (pl)
DK (1) DK3317300T3 (pl)
ES (1) ES2848391T3 (pl)
HR (1) HRP20210152T1 (pl)
HU (1) HUE053128T2 (pl)
LT (1) LT3317300T (pl)
PL (1) PL3317300T3 (pl)
PT (1) PT3317300T (pl)
RS (1) RS61444B1 (pl)
SI (1) SI3317300T1 (pl)
WO (1) WO2017001681A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107417792B (zh) * 2017-08-29 2020-07-03 天津医科大学总医院 抗cd40-her2双特异性单链抗体及其在制备抗肿瘤药物中的应用
WO2019098563A1 (ko) 2017-11-20 2019-05-23 주식회사 엘지화학 회전식 디스크 시스템을 활용한 중금속 정성 및 정량 분석 디바이스 및 분석 방법
CN112313333A (zh) 2018-05-10 2021-02-02 秘来生物制剂株式会社 包含抗体的抗原结合区、融合生理活性肽的人工蛋白质
US12649792B2 (en) 2019-05-06 2026-06-09 Brown University Bispecific antibodies against CHI3L1 and PD1 with enhanced T cell-mediated cytotoxic effects on tumor cells
CN114573705B (zh) * 2022-03-17 2024-05-14 杭州师范大学 特异性启动抗乙型肝炎病毒t细胞免疫的双特异性抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
PT2857516T (pt) * 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
JP3803790B2 (ja) * 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
SI2242771T1 (sl) * 2007-12-14 2013-09-30 Bristol-Myers Squibb Company Vezane molekule k humanemu ox40 receptorju
EP2684896A1 (en) * 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
US10647768B2 (en) * 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
CN107250161A (zh) * 2015-01-26 2017-10-13 宏观基因有限公司 包含dr5‑结合结构域的多价分子

Also Published As

Publication number Publication date
ES2848391T3 (es) 2021-08-09
KR102933838B1 (ko) 2026-03-05
RS61444B1 (sr) 2021-03-31
EP3317300A1 (en) 2018-05-09
EP3112381A1 (en) 2017-01-04
HUE053128T2 (hu) 2021-06-28
HRP20210152T1 (hr) 2021-03-19
JP6876006B2 (ja) 2021-05-26
US20180250396A1 (en) 2018-09-06
CA2990517A1 (en) 2017-01-05
AU2016285118B2 (en) 2021-12-16
LT3317300T (lt) 2021-05-10
SI3317300T1 (sl) 2021-04-30
WO2017001681A8 (en) 2018-03-29
EP3317300B1 (en) 2020-11-18
AU2016285118A1 (en) 2018-02-22
CA2990517C (en) 2023-08-29
KR20180053639A (ko) 2018-05-23
DK3317300T3 (da) 2021-02-01
US10813995B2 (en) 2020-10-27
WO2017001681A1 (en) 2017-01-05
CY1123839T1 (el) 2022-05-27
PT3317300T (pt) 2021-02-04
CN108602886A (zh) 2018-09-28
AU2016285118A9 (en) 2019-08-01
CN108602886B (zh) 2021-10-15
JP2018525347A (ja) 2018-09-06

Similar Documents

Publication Publication Date Title
IL261163B (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
IL251963A0 (en) Anti-pd-1 antibodies
LT3119808T (lt) Antikūnų kompozicijos vėžio gydymui
DK3344654T3 (da) Anti-lag-3-antistoffer
LT3240801T (lt) Kombinuota navikų imunoterapija
DK3126395T3 (da) Multispecifikke antistoffer
EP3319984C0 (en) TAU LINKING ANTIBODIES
IL249512B (en) Antibodies binding axl
DK3258951T3 (da) Anti-pvrig antistoffer og fremgangsmåder for anvendelse
HUE053457T2 (hu) Multispecifikus ellenanyag-konstrukciók
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
EP3319983C0 (en) TAU LINKING ANTIBODIES
HUE060878T2 (hu) Anti-transztiretin antitestek
IL291164A (en) Anti-nme antibody
DK3250593T3 (da) Anti-transthyretin-antistoffer
HRP20251683T1 (hr) Humanizirana anti-acth antitijela i njihova uporaba
IL272487B (en) Antibodies useful in cancer diagnosis
PL3092003T3 (pl) Nowe przeciwciało przeciw netrynie-1
IL250507B (en) Anti-ck8 antibodies for use in the treatment of cancers
EP3310915A4 (en) TUMOR IMMUNOTHERAPY
IL255560B (en) Macropinocytosis in cancer
EP3160502B1 (en) BI-SPECIFIC ANTIBODIES ANTI-IL4-IL13
LT3628731T (lt) Naujas antipresepsino antikūnas
LT3178931T (lt) Anti-orai1 antikūnas
LT3126391T (lt) Hpa-1a antikūnai